NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Key Takeaways Novo Nordisk will move amycretin into phase III trials for weight management starting in Q1 2026. The decision follows phase II feedback from regulators on both subcutaneous and oral amycretin. Amycretin aims to offer a long-acting, convenient option for obesity and type 2 diabetes treatment.Novo Nordisk (NVO) announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being developed for subcutaneous and oral administration.Shares of this Denmark-b ...